Table II.
Subgroup analysis of unmatched baseline characteristics and outcomes
| Characteristics | Before propensity matching |
P value | ||||
|---|---|---|---|---|---|---|
| TNFi (n = 102) | No TNFi (n = 32,057) | P value | MTX (n = 128) | No MTX (n = 31982) | ||
| Demographics | ||||||
| Age at index, y ± SD | 49.7 ± 15.6 | 53.2 ± 18.9 | .0606 | 58.7 ± 14.9 | 53.2 ± 18.9 | .0011 |
| Female, n (%) | 62 (60.7) | 17540 (54.7) | .2189 | 93 (72.7) | 17461 (54.6) | <.0001 |
| White, n (%) | 46 (45.1) | 11040 (34.4) | .0237 | 53 (41.4) | 11011 (34.4) | .0974 |
| Comorbidities, n (%) | ||||||
| Diseases of the digestive system | 51 (50.0) | 5615 (17.5) | <.0001 | 62 (48.4) | 5599 (17.5) | <.0001 |
| Diseases of the musculoskeletal system and connective tissue | 58 (56.9) | 6490 (20.3) | <.0001 | 98 (76.6) | 6424 (20.1) | <.0001 |
| Diseases of the nervous system | 38 (37.3) | 5326 (16.6) | <.0001 | 63 (49.2) | 5286 (16.5) | <.0001 |
| Diseases of the blood and blood-forming organs | 37 (36.3) | 4115 (12.8) | <.0001 | 58 (45.3) | 4084 (12.8) | <.0001 |
| Diseases of the circulatory system | 50 (49.0) | 9644 (30.1) | <.0001 | 88 (68.8) | 9581 (30.0) | <.0001 |
| Diseases of the skin and subcutaneous tissue | 28 (27.5) | 2351 (7.3) | <.0001 | 36 (28.1) | 2339 (7.3) | <.0001 |
| Diabetes mellitus | 11 (10.8) | 4037 (12.6) | .5824 | 33 (25.8) | 4007 (12.5) | <.0001 |
| Body mass index 30-39.9 kg/m2 | 18 (17.6) | 2945 (9.2) | .0032 | 25 (19.5) | 2930 (9.2) | <.0001 |
| 45-day outcomes, n (%) | ||||||
| Hospitalization | 24 (23.5) | 6378 (19.9) | .3588 | 40 (31.3) | 6349 (19.9) | .0013 |
| Death | N/A∗ | 1979 (6.2) | - | 12 (9.4) | 1964 (6.1) | .1286 |
MTX, Methotrexate; N/A, not available; SD, standard deviation; TNFi, tumor necrosis factor inhibitor.
∗
TriNetX obfuscates patient counts ≤10 to safeguard protected health information.